The present invention relates to compound of Formula (I) ##STR00001##
containing carbon-carbon linker, a stereoisomer, a tautomer, a pharmaceutically acceptable salt, a pharmaceutically acceptable solvate, a prodrug, a polymorph, N-oxide, S-oxide, or a carboxylic acid isostere thereof; processes for their preparation; pharmaceutical compositions comprising said compounds; and their use for the treatment of the diseases or disorders mediated by GPR120 receptor.

The present invention relates to compound of Formula (I) ##STR00001##
containing carbon-carbon linker, a stereoisomer, a tautomer, a pharmaceutically acceptable salt, a pharmaceutically acceptable solvate, a prodrug, a polymorph, N-oxide, S-oxide, or a carboxylic acid isostere thereof; processes for their preparation; pharmaceutical compositions comprising said compounds; and their use for the treatment of the diseases or disorders mediated by GPR120 receptor.

Provided are novel carbonohydrazonoyl dicyanide compounds including two or more aryl or heteroaryl groups connected via a linker and uses thereof.

Provided are novel carbonohydrazonoyl dicyanide compounds including two or more aryl or heteroaryl groups connected via a linker and uses thereof.

Phenol derivatives of general formula (I) and (II), wherein meanings of the substituents are indicated in the description, their pharmaceutically acceptable salts, together with the processes for their preparation, their use as antimicrobial, antibacterial, bactericide agents and the corresponding pharmaceutical compositions are disclosed.

The present disclosure relates to compounds, compositions and supplements that are capable of treating obesity. The disclosure further relates to methods of treating obesity in a subject in need thereof.

Disclosed are compounds of formula (I) below and pharmaceutically acceptable salts thereof: (I), in which each of variables R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, A.sub.1, A.sub.2, A.sub.3, A.sub.4, X and Y is defined herein. Also disclosed are methods for reducing the glycemic level and treating glucagon-associated disorders with a compound of formula (I) or a salt thereof and a pharmaceutical composition containing same. ##STR00001##

Disclosed are compounds of formula (I) below and pharmaceutically acceptable salts thereof: (I), in which each of variables R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, A.sub.1, A.sub.2, A.sub.3, A.sub.4, X and Y is defined herein. Also disclosed are methods for reducing the glycemic level and treating glucagon-associated disorders with a compound of formula (I) or a salt thereof and a pharmaceutical composition containing same. ##STR00001##

The present technology is directed to compounds that inhibit of the interaction of RNA-binding proteins with RNA, intermediates thereof, compositions thereof, and methods of treatment utilizing such compounds, where the compounds are of Formula (I).

The present technology is directed to compounds that inhibit of the interaction of RNA-binding proteins with RNA, intermediates thereof, compositions thereof, and methods of treatment utilizing such compounds, where the compounds are of Formula (I).